title: Reining in the pharmacological enhancement train: we should remain vigilant about regulatory standards for prescribing controlled substances.
abstract: This article challenges recent assumptions that physicians may ethically and legally prescribe psychopharmacological enhancement drugs to patients and the counterintuitive notion that in some cases ingesting an enhancement drug constitutes the more ethical choice than foregoing this option. Enhancement proponents have touted modafinil as an ideal mechanism to improve concentration, alertness, and forego sleep and keep pace with our society's demands. However, patients who use modafinil for these reasons risk potentially severe side effects and addiction, and face unintended consequences related to their cognitive, emotive, and physiological functioning. Importantly, prescribing a controlled substance such as modafinil for performance enhancement and sleep avoidance runs contrary to a physician's ethical duty to the patient and the standard of practice set forth in legal requirements governing the prescription of controlled substances.
authors.affiliation: Indiana University Center for Bioethics, IN, USA.
authors.forename: Katherine
authors.initials: K
authors.lastname: Drabiak-Syed
mesh_terms: D001559:Benzhydryl Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D000697:Central Nervous System Stimulants / Q000009:adverse effects / Q000627:therapeutic use*; D003071:Cognition / Q000187:drug effects*; D017277:Drug Approval; D004363:Drug Utilization; D004335:Drug and Narcotic Control; D005221:Fatigue / Q000188:drug therapy*; D006801:Humans; D000077408:Modafinil; D014481:United States; D014486:United States Food and Drug Administration; D014940:Work Schedule Tolerance
chemical_list: D001559:Benzhydryl Compounds; D000697:Central Nervous System Stimulants; D000077408:Modafinil